Revenue: As of FY2025 Q3, the actual value is USD 722 K.

EPS: As of FY2025 Q3, the actual value is USD -0.91.

EBIT: As of FY2025 Q3, the actual value is USD 598 K.

Segment Revenue

• NanoVibronix: $1,738 thousand for the nine months ended September 30, 2025.
• ENvue: $503 thousand for the nine months ended September 30, 2025.

Operational Metrics

• Gross Profit: $523 thousand for the nine months ended September 30, 2025, compared to $1,225 thousand for the same period in 2024, a decrease of 57%.
• Operating Loss: $8,075 thousand for the nine months ended September 30, 2025, compared to $2,212 thousand for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $6,696 thousand for the nine months ended September 30, 2025.
• Net Cash Provided by Financing Activities: $12,820 thousand for the nine months ended September 30, 2025.

Unique Metrics

• Goodwill: $38,631 thousand as of September 30, 2025, resulting from the ENvue merger.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue its operations through its subsidiaries, focusing on non-invasive biological response-activating devices and enteral feeding medical devices. The company expects to incur future net losses and will depend on raising additional funds to support its operations.
• Non-Core Business: The company has identified inaccuracies in its 510(k) application for the PainShield MD Plus product and has decided to halt future sales of this product.